Clinical trials
Withdrawn Phase 1 trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 4 |
| 2020 | 2 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 7 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 65 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Beijing Boren Hospital | 9 |
| Shanghai Pudong Hospital | 3 |
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Kousai Bio Co., Ltd. | 2 |
| Pfizer | 2 |
| Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| 3D Medicines (Beijing) Co., Ltd. | 1 |
| Allist Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 7 |
| Autoimmune Diseases | 4 |
| Leukemia, Myeloid, Acute | 4 |
| Lupus Erythematosus, Systemic | 4 |
| Leukemia | 3 |
| Lymphoma, B-Cell | 3 |
| Multiple Sclerosis | 3 |
| Myositis | 3 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.